摘要:
Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length S. aureus sequence. A derivative of SEQ ID NO 1 containing an amino terminal his-tag was found to produce a protective immune response against S. aureus.
摘要翻译:公开了包含与SEQ ID NO 1结构相关的氨基酸序列的多肽以及这种多肽及其组合物的用途。 SEQ ID NO 1是全长金黄色葡萄球菌序列。 发现含有氨基末端his标签的SEQ ID NO 1的衍生物产生针对金黄色葡萄球菌的保护性免疫应答。
摘要:
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length S. aureus sequence. A derivative of SEQ ID NO: 1 containing an amino terminus his-tag was found to produce a protective immune response against S. aureus.
摘要翻译:本发明的特征在于包含与SEQ ID NO:1结构相关的氨基酸序列的多肽及其多肽及其组合物的用途。 SEQ ID NO:1是全长金黄色葡萄球菌序列。 发现含有氨基末端his标签的SEQ ID NO:1的衍生物产生针对金黄色葡萄球菌的保护性免疫应答。
摘要:
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 or a fragment thereof, S. aureus AhpC-AhpF compositions, and uses of such polypeptides and compositions. SEQ ID NO: 1 has a full length S. aureus AhpC sequence. A derivative of SEQ ID NO: 1 containing an amino His-tag and three additional carboxylamino acids was found to produce a protective immune response against S. aureus.
摘要翻译:本发明的特征在于包含与SEQ ID NO:1结构相关的氨基酸序列或其片段,金黄色葡萄球菌AhpC-AhpF组合物以及这些多肽和组合物的用途的多肽。 SEQ ID NO:1具有全长金黄色葡萄球菌AhpC序列。 发现含有氨基His-标签和三个另外的羧基氨基酸的SEQ ID NO:1的衍生物产生针对金黄色葡萄球菌的保护性免疫应答。
摘要:
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 or a fragment thereof, S. aureus AhpC-AhpF compositions, and uses of such polypeptides and compositions. SEQ ID NO: 1 has a full length S. aureus AhpC sequence. A derivative of SEQ ID NO: 1 containing an amino His-tag and three additional carboxyl amino acids was found to produce a protective immune response against S. aureus. MGHHHHHHHHHHSSGHIEGRHMSLINKEILPFTAQAFDPKKDQFKEVTQE DLKGSWSVVCFYPADFSFVCPTELEDLQNQYEELQKLGVNVFSVSTDTHF VHKAWHDHSDAISKITYTMIGDPSQTITRNDVLDEATGLAQRGTFIIDPD GVVQASEINADGIGRDASTLAHKIKAAQYVRKNPGEVCPAKWEEGAKTLQ PGLDLVGKIAEQ
摘要翻译:本发明的特征在于包含与SEQ ID NO:1结构相关的氨基酸序列或其片段,金黄色葡萄球菌AhpC-AhpF组合物以及这些多肽和组合物的用途的多肽。 SEQ ID NO:1具有全长金黄色葡萄球菌AhpC序列。 发现含有氨基His标签和三个另外的羧基氨基酸的SEQ ID NO:1的衍生物产生针对金黄色葡萄球菌的保护性免疫应答。 Q Q H HI R H INK INK S HI Q Q Q Q
摘要:
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 or a fragment thereof, S. aureus AhpC-AhpF compositions, and uses of such polypeptides and compositions. SEQ ID NO: 1 has a full length S. aureus AhpC sequence. A derivative of SEQ ID NO: 1 containing an amino His-tag and three additional carboxyl amino acids was found to produce a protective immune response against S. aureus. MGHHHHHHHHHHSSGHIEGRHMSLINKEILPFTAQAFDPKKDQFKEVTQE DLKGSWSVVCFYPADFSFVCPTELEDLQNQYEELQKLGVNVFSVSTDTHF VHKAWHDHSDAISKITYTMIGDPSQTITRNDVLDEATGLAQRGTFIIDPD GVVQASEINADGIGRDASTLAHKIKAAQYVRKNPGEVCPAKWEEGAKTLQ PGLDLVGKIAEQ
摘要翻译:本发明的特征在于包含与SEQ ID NO:1结构相关的氨基酸序列或其片段,金黄色葡萄球菌AhpC-AhpF组合物以及这些多肽和组合物的用途的多肽。 SEQ ID NO:1具有全长金黄色葡萄球菌AhpC序列。 发现含有氨基His标签和三个另外的羧基氨基酸的SEQ ID NO:1的衍生物产生针对金黄色葡萄球菌的保护性免疫应答。
摘要:
Various embodiments concern a gimbaled flexure having a dual stage actuation structure. The flexure comprises a gimbal which includes a pair of spring arms, a pair of struts, and a tongue between the spring arms. A motor is mounted on the gimbal. The motor comprises a top side and a bottom side opposite the top side. The bottom side of the motor faces the flexure. A stiffener is mounted on the top side of the motor. At least one layer of adhesive is located between the stiffener and the motor and bonded to the stiffener and the motor. The gimbaled flexure includes a slider mounting for attaching a slider, such as to the tongue. The motor bends the struts to move the slider mounting about a tracking axis while the stiffener limits the degree of bending of the motor.
摘要:
A fitting for use with corrugated tubing, the fitting comprising: a nut having a passage therethrough for receiving the tubing, the tubing being corrugated tubing having a series of peaks and valleys; a plurality of retainers positioned forward of the nut, the retainers having a sealing surface for placement in a valley of the corrugated tubing; a body having an annular pocket formed circumferentially around the retainers, the body having a body sealing surface, wherein upon sealing, the tubing is compressed between the sealing surface and the body sealing surface; a spring positioned within a cavity in the retainers, the spring driving the retainers into the pocket when the fitting is not sealed.
摘要:
Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.
摘要:
Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.